Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis

Main Article Content

Francisco Kerdel
Christina Don
Renata Block
Caitlin Lewis
Rhonda Schreiber

Keywords

Psoriasis, Calcipotriene, Foam

Abstract

Abstract not available.

References

1. Gupta R, Debbaneh MG, Liao W, Genetic Epidemiology of Psoriasis,. Curr Dermatol Rep. 2014 March; 3(1):61 78.

2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136 9.

3. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv .2012 Oct;9(10):1263 71.

4. Stein Gold LF. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherenc e. Semin Cutan Med Surg. 2016 Mar;35(2 Suppl 2):S36 44; quiz S45.

5. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Charact eri stics Can Influence and Improve Patient Outcomes J Drugs Dermatol . 2019 Feb 1;18(2s):s100 s107.

6. Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 J ul ;94(1):46 53.

7. Feldman , S. R., Mills, M., Brundage, T., & Eastman, W. J. (2013, March). A multicenter, randomized, double blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque type pso riasis of the scalp. JDD, 12(3), 300 306.

8. Data on File, Mayne Pharma, Inc.